How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches.


Journal

AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133

Informations de publication

Date de publication:
Aug 2019
Historique:
pubmed: 12 12 2018
medline: 8 10 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

In the field of biomedical HIV prevention, researchers have meaningfully incorporated behavioral and social sciences research (BSSR) into numerous clinical trials, though the timing and degree of integration have been highly variable. The literature offers few frameworks that systematically characterize these collaborations. To fill this gap, we developed a typology of BSSR approaches within biomedical HIV prevention research. Focusing on trials that had safety and/or efficacy endpoints, we identified five approaches for combining BSSR and clinical research: formative, embedded, parallel, explanatory, and implications. We describe each approach and provide illustrative examples. By offering a shared vocabulary for distinguishing the timing and design of collaborative BSSR and clinical research, this typology can facilitate greater transparency in collaborators' expectations and responsibilities, and help collaborators address challenges likely to be associated with such interdisciplinary research.

Identifiants

pubmed: 30535615
doi: 10.1007/s10461-018-2358-0
pii: 10.1007/s10461-018-2358-0
pmc: PMC6647486
mid: NIHMS1021094
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2146-2154

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI064518
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI127024
Pays : United States
Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases
ID : 1R01AI127024

Références

J Infect Dis. 2005 Mar 1;191(5):654-65
pubmed: 15688278
AIDS Care. 2005 Jan;17(1):46-57
pubmed: 15832833
Contemp Clin Trials. 2007 Jan;28(1):59-67
pubmed: 17000137
Am J Prev Med. 2008 Aug;35(2 Suppl):S211-24
pubmed: 18619402
J Empir Res Hum Res Ethics. 2006 Dec;1(4):45-60
pubmed: 19385837
BMJ. 2009 Sep 10;339:b3496
pubmed: 19744976
AIDS. 2010 Mar 13;24(5):621-35
pubmed: 20179575
N Engl J Med. 2010 Jun 17;362(24):2271-81
pubmed: 20554982
PLoS One. 2010 Jul 21;5(7):e11632
pubmed: 20657774
PLoS One. 2010 Jul 21;5(7):e11600
pubmed: 20657778
Lancet. 2010 Oct 16;376(9749):1329-37
pubmed: 20851460
AIDS Behav. 2012 Feb;16(2):412-21
pubmed: 21656146
Vaccine. 2011 Oct 26;29(46):8417-28
pubmed: 21864626
J Int AIDS Soc. 2011 Sep 27;14 Suppl 2:S3
pubmed: 21968079
J Int AIDS Soc. 2011 Sep 27;14 Suppl 2:S4
pubmed: 21968091
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):463-8
pubmed: 22267018
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
J Law Med Ethics. 2012 Winter;40(4):1008-24
pubmed: 23289702
BMJ Open. 2013 Jun 20;3(6):null
pubmed: 23794542
PLoS One. 2014 Mar 06;9(3):e90938
pubmed: 24603848
Contemp Clin Trials. 2014 Jul;38(2):338-43
pubmed: 24937019
BMC Womens Health. 2014 Jul 28;14:88
pubmed: 25065834
J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):555-63
pubmed: 25393942
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):578-84
pubmed: 25761233
PLoS One. 2015 Apr 13;10(4):e0125458
pubmed: 25867624
J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):452-61
pubmed: 26536315
AIDS Behav. 2016 Sep;20 Suppl 2:281-7
pubmed: 27011377
AIDS Behav. 2016 Sep;20 Suppl 2:273-80
pubmed: 27435076
Genet Med. 2017 Jul;19(7):743-750
pubmed: 27929525
Health Psychol. 2017 Jan;36(1):5-7
pubmed: 28045300
J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):371-381
pubmed: 28418987

Auteurs

Amy Corneli (A)

Department of Population Health Sciences, Duke University School of Medicine, 215 Morris Street, Suite 210, Durham, NC, 27701, USA. amy.corneli@duke.edu.
Duke Clinical Research Institute, Duke University, Durham, NC, USA. amy.corneli@duke.edu.

Karen Meagher (K)

Department of Social Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.

Gail Henderson (G)

Department of Social Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.

Holly Peay (H)

RTI International, Research Triangle Park, NC, USA.

Stuart Rennie (S)

Department of Social Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH